Baker’s Orwellian drug pricing policy
AG referral is the criminalization of a policy dispute
THE BAKER ADMINISTRATION recently released its budget proposal for one of their most high-profile issues: drug prices in the Medicaid program. To the surprise of many in the biopharmaceutical industry, there are some promising initiatives in the proposal from an administration that is thought to be hostile to the industry on drug prices. By far the most(...)